EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease

Carl Eriksson iD, Jonas Söderling, Sara Karlqvist, Gabriella Bröms, Åsa H Everhov, Daniel Bergemalm, Jonas F Ludvigsson, SWIBREG study group, Ola Olén, Jonas Halfvarson

Digestive Diseases and Sciences · 2023

DOI: 10.1007/s10620-023-07897-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2023. Verfasst von Carl Eriksson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. carl.eriksson@regionorebrolan.se. Hauptthemen laut MEDLINE: Crohn Disease, Biological Products. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Pharmaceuticals, Örebro University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There are little data on positioning biologics in Crohn's disease (CD). AIMS: We aimed to assess the comparative effectiveness and safety of ustekinumab vs tumour necrosis factor-alpha (anti-TNF) agents after first-line treatment with anti-TNF in CD. METHODS: We used Swedish nationwide registers to identify patients with CD, exposed to anti-TNF who initiated second-line biologic treatment with ustekinumab or second-line anti-TNF therapy. Nearest neighbour 1:1 propensity score matching (PSM) was used to balance the groups. The primary outcome was 3-year drug survival used as a proxy for effectiveness. Secondary outcomes included drug survival without hospital admission, CD-related surgery, antibiotics, hospitalization due to infection and exposure to corticosteroids. RESULTS: Some 312 patients remained after PSM. Drug survival at 3 years was 35% (95% CI 26-44%) in ustekinumab compared to 36% (95% CI 28-44%) in anti-TNF-treated patients (p = 0.72). No statistically significant differences were observed between the groups in 3-year survival without hospital admission (72% vs 70%, p = 0.99), surgery (87% vs 92%, p = 0.17), hospital admission due to infection (92% vs 92%, p = 0.31) or prescription of antibiotics (49% vs 50%, p = 0.56). The proportion of patients continuing second-line biologic therapy did not differ by reason for ending first-line anti-TNF (lack of response vs intolerance) or by type of first-line anti-TNF (adalimumab vs infliximab). CONCLUSION: Based on data from Swedish routine care, no clinically relevant differences in effectiveness or safety of second-line ustekinumab vs anti-TNF treatment were observed in patients with CD with prior exposure to anti-TNF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseBiological ProductsHumansUstekinumabTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAntibodies, Monoclonal, HumanizedAdalimumabInfliximabBiological FactorsNecrosisTreatment Outcome

Stichwörter der Autor:innen

Anti-TNFComparative effectivenessComparative safetyCrohn’s diseasePopulation-based studyUstekinumab

Substanzen

UstekinumabTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAntibodies, Monoclonal, HumanizedAdalimumabInfliximabBiological FactorsBiological Products

Autor:innen und Institutionen

  • Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. carl.eriksson@regionorebrolan.se.
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. carl.eriksson@regionorebrolan.se.
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Division of Gastroenterology, Department of Specialist Medicine, Danderyd Hospital, Stockholm, Sweden.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Carl Eriksson

Förderung

  • Janssen Pharmaceuticals
  • Örebro University

Zitieren

APA

Eriksson, C., Söderling, J., Karlqvist, S., Bröms, G., Everhov, Å. H., Bergemalm, D., Ludvigsson, J. F., SWIBREG study group, Olén, O., & Halfvarson, J. (2023). Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-023-07897-2

Vancouver

Eriksson C, Söderling J, Karlqvist S, Bröms G, Everhov ÅH, Bergemalm D, et al. Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease. Digestive Diseases and Sciences. 2023. doi:10.1007/s10620-023-07897-2

BibTeX
@article{Eriksson2023,
  author = {Eriksson, Carl and Söderling, Jonas and Karlqvist, Sara and Bröms, Gabriella and Everhov, Åsa H and Bergemalm, Daniel and Ludvigsson, Jonas F and SWIBREG study group, SWIBREG study group and Olén, Ola and Halfvarson, Jonas},
  title = {Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease},
  journal = {Digestive Diseases and Sciences},
  year = {2023},
  doi = {10.1007/s10620-023-07897-2}
}
Kostenlos starten →